Detalles de la búsqueda
1.
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Ann Rheum Dis
; 2024 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38569851
2.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
N Engl J Med
; 382(3): 211-221, 2020 01 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-31851795
3.
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Ann Rheum Dis
; 82(5): 639-645, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36690388
4.
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
Rheumatology (Oxford)
; 62(4): 1526-1534, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36018235
5.
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
Mod Rheumatol
; 33(1): 134-144, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35134970
6.
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Ann Rheum Dis
; 81(7): 962-969, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35580976
7.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Ann Rheum Dis
; 81(7): 951-961, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35338035
8.
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Ann Rheum Dis
; 81(4): 496-506, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35144924
9.
Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials.
Rheumatology (Oxford)
; 61(12): 4731-4740, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274691
10.
Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
Rheumatology (Oxford)
; 61(5): 1900-1910, 2022 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34528084
11.
Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus.
Rheumatology (Oxford)
; 60(12): 5854-5862, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33629110
12.
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
Lupus
; 30(8): 1254-1263, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33977796
13.
The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
Int J Mol Sci
; 22(20)2021 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34681945
14.
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
Mod Rheumatol
; 31(1): 1-12, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32814461
15.
Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Mod Rheumatol
; 30(1): 101-108, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30793642
16.
Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Mod Rheumatol
; 30(1): 93-100, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30791804
17.
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.
Ann Rheum Dis
; 77(5): 706-713, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29420200
18.
Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
Pain Pract
; 18(4): 505-514, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28898536
19.
Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
J Clin Psychopharmacol
; 35(1): 77-81, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25514064
20.
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg.
Ann Rheum Dis
; 78(11): e122, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373881